Lung transplantation: advances in immunosuppression.
Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab. expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another. or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.
Bush
Errol L
EL
Department of Surgery, Duke University Medical Center, DUMC Box 3443, Durham, NC 27710, USA.
Lin
Shu S
SS
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D016040:Lung Transplantation; D015182:Lymphatic Irradiation; D017893:Photopheresis
D000964:Antimetabolites, Antineoplastic; D007166:Immunosuppressive Agents